Female-controlled methods to prevent sexual transmission of HIV

AIDS, Supplement

Volumn 10, Issue 3, 1996, Pages

  Elias, Christopher J ^a   Coggins, Christiana ^b  

^a POPULATION COUNCIL   (Thailand)

^b POPULATION COUNCIL   (United States)

Author keywords

Barrier methods; Female condoms; Female controlled methods; Heterosexual transmission of HIV; Microbicides

Indexed keywords

CONFERENCE PAPER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; ORGANIZATION AND MANAGEMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS TRANSMISSION;

AMERICAS; BARRIER METHODS; CLINICAL RESEARCH; CLINICAL TRIALS; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISEASES; ECONOMIC FACTORS; FAMILY PLANNING; HIV INFECTIONS--PREVENTION AND CONTROL; INFECTIONS; LITERATURE REVIEW; NORTH AMERICA; NORTHERN AMERICA; REPRODUCTIVE TRACT INFECTIONS; RESEARCH AND DEVELOPMENT; RESEARCH METHODOLOGY; SEXUALLY TRANSMITTED DISEASES--PREVENTION AND CONTROL; SPERMICIDAL CONTRACEPTIVE AGENTS; TECHNOLOGY; UNITED STATES; VIRAL DISEASES;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS;

EID: 0029806126     PISSN: 13502840     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Centers for Disease Control and Prevention: Update: mortality attributable to HIV infection among persons aged 25-44 years: United States, 1994. MMWR 1996, 45:121-125.
2. World Health Organization/Global Program on AIDS: The Current Global Situation of the HIV/AIDS Pandemic, Reported Cases, 15 December 1995. Geneva: WHO/GPA; 1995.
3. Wasserheit JN: Epidemiological synergy: interrelationships between HIV infection and other STDs. In AIDS and Women's Health: Science for Policy and Action. Edited by Chen L, Sepulveda J, Segal S. New York: Plenum Press; 1991:42-72
4. [reprinted in Sex Transm Dis 1992, 19:61-77].
5. Centers for Disease Control and Prevention: Update: barrier protection against HIV and other sexually transmitted diseases. MMWR 1993, 42:589-597.
6. Heise LL, Elias CJ: Transforming AIDS prevention to meet women's needs: a focus on developing countries. Soc Sci Med 1994, 40:931-943.
7. Gupta GR, Weiss E: Women and AIDS: developing a new health strategy. ICRW Policy Series. Washington, DC: International Center for Research on Women; October 1993.
8. Gollub EL, French P, Latka M: The women's safer sex hierarchy: initial responses to counseling on women's methods of STD/ HIV prevention at an STD clinic. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoD583].
9. Macaluso M, Carew B, Artz L, et al.: A study of the prophylactic efficacy of the female condom among high risk women. Society for Epidemiologic Research 29th Annual Meeting. Boston, June 1996 [abstract 311].
10. Grosskurth C, Mosha F, Todd J, et al.: Impact of improved treatment of STDs on HIV infection. Lancet 1995, 346:530 -536.
11. International Working Group on Vaginal Microbicides: Recommendations for the development of vaginal microbicides. AIDS 1996, 10:UNAIDS1-UNAIDS6.
12. Alexander NJ: Barriers to sexually transmitted diseases. Sci Med 1996, 3:32-41.
13. Rosenberg M, Gollub E: Methods women can use that may prevent sexually transmitted disease, including HIV. Am J Public Health 1992, 11:1473-1478.
14. Herndon N: Scientists search for HIV prevention methods women can control. AIDScaptions. Arlington, VA: Family Health International; November 1995:11-13.
15. The Gray Sheet. FDC Rep 1993, 19:3-4.
16. Anonymous: Femidom® - a condom for women. Med Lett Drugs Therapeut 1993, 35:123-124.
17. Trussell J, Sturgen K, Strickler J, Dominik R: Comparative contraceptive efficacy of the female condom and other barrier methods. Fam Plann Perspect 1994, 26:66-72.
18. Bounds W, Guillebaud J, Newman GB: Female condom (Femidom®). A clinical study of its use-effectiveness and patient acceptability. Br J Fam Plann 1992, 18:36-41.
19. Drew WL, Blair M, Miner RC, Conant M: Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990, 17:110-112.
20. Anonymous: Clinics first to receive female condom. Contraceptive Technology Update 1993, 14:50-51.
21. Cates W, Stewart FH, Trussell J: The quest for women's prophylactic methods: hopes vs science. Am J Public Health 1992, 82:1479-1482.
22. Zekeng L, Feldblum PJ, Oliver RM, Kaptue L: Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS 1993, 7:725-731.
23. Feldblum P: Efficacy of spermicide use and condom use by HIV-discordant couples in Zambia. Int J STD AIDS (in press).
24. Minutes of The Fifth Meeting of the International Working Group on Vaginal Microbicides. London, October 1995.
25. Malkovsky M, Newell A, Dalgleish AG: Inactivation of HIV by nonoxynol-9. Lancet 1988, i:645.
26. Judson FN, Ehret JM, Bodin GF, Levin MJ, Reitmeijer AM: In vitro evaluations of condoms with and without nonoxynol-9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus 2 and human immunodeficiency virus. Sex Transm Dis 1989, 16:51-56.
27. Jones BM, Geary I, Lee ME, Duerden BI: Susceptibility of Haemophilus ducreyi to spermicidal compounds in vitro. Genitorurin Med 1991, 67:268-269.
28. Kreiss J, Ngugi E, Holmes K, et al.: Efficacy of nonxoynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992, 268:477-482.
29. Weir SW, Feldblum PJ, Zekeng L, Roddy R: The use of nonoxynol-9 for protection against cervical gonorrhea. Am J Public Health 1994, 84:910-914.
30. Bird KD: The use of spermicide containing nonoxynol-9 in the prevention of HIV infection. AIDS 1991, 5:791-796.
31. Stone AB, Hitchcock PJ: Vaginal microbicides for preventing the sexual transmission of HIV. AIDS 1994, 8 (suppl 1):285-293.
32. Roddy RE, Cordero M, Cordero C, Fortney JA: A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993, 4:165-170.
33. Niruthisard S, Roddy RE, Chulivongse S: Effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis 1991, 18:176-179.
34. Goeman J, Ndoye I, Sakho LM, et al.: Frequent use of menfegol spermicidal vaginal foaming tablets associated with high incidence of genital lesions. J Infect Dis 1995, 171:1611-1614.
35. Cleary J: Female Condom: Efficacy, Acceptability and Relationship to the Women's Hierarchy of Risk Reduction. Albany, NY: NY State Department of Health; 1994.
36. Thompson K, Malamud D, Storey BT: Assessment of the antimicrobial agent C31G as a spermicide: comparison with nonoxynol-9. Contraception 1996, 53:313-318.
37. Doctors creating AIDS gels. The Bergen Record, 14 February 1996.
38. Voeller B, Anderson DJ: pH and Related Factors in the Urogenital Tract and Rectum that Affect HIV-1 Transmission. [Mariposa Occasional Paper No. 16]. Topanga, CA: The Mariposa Education and Research Foundation; 1992.
39. Redondo-Lopez V, Cook RL, Sobel JD: Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990, 12:856-872.
40. South to South Cooperation in Reproductive Health: Biennial Report 1993-95. Salvador, Bahia, Brazil: South to South Cooperation in Reproductive Health; 1995.
41. Neurath AR, Jiang S, Strick N, Lin K, Li Y, Debnath AK: Bovine β-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nature Med 1996, 2:230-234.
42. Pearce-Pratt R, Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of HIV-1. Biol Reprod 1996, 54:173-182.
43. Pauwels R, De Clercq E: Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:211-221.
44. Miller CJ, Gerstein MJ, Davis RC, Katz DH: n-Docosanol prevents vaginal transmission of SIVmac251 in rhesus macaques. Eighth International Conference on Antiviral Research. Santa Fe, April 1995 [abstract 97].
45. Lidak pharmaceuticals announces that N-docosonal... [press release]. PR Newswire, 25 April 1995.
46. Haney D: Associated Press News Release. 20 May 1996.
47. Elias CJ, Heise LL: Challenges for the development of female-controlled vaginal microbicides. AIDS 1994, 8:1-9.
48. Mosteller F: Editorial: the promise of risk-based allocation trials in assessing new treatments. Am J Public Health 1996, 86:622-623.
49. Finkelstein MO, Levin B, Robbins H: Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal. Am J Public Health 1996, 86:691-695.
50. Finkelstein MO, Levin B, Robbins H: Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples. Am J Public Health 1996, 86:696-705.
51. Parker R: Empowerment, community mobilisation and social change in the face of HIV/AIDS. XI Interntional Conference on AIDS. Vancouver, July 1996 [abstract Tu06].